BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 30560880)

  • 21. Structural Determinants of the APOBEC3G N-Terminal Domain for HIV-1 RNA Association.
    Fukuda H; Li S; Sardo L; Smith JL; Yamashita K; Sarca AD; Shirakawa K; Standley DM; Takaori-Kondo A; Izumi T
    Front Cell Infect Microbiol; 2019; 9():129. PubMed ID: 31165049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. APOBEC3G-Regulated Host Factors Interfere with Measles Virus Replication: Role of REDD1 and Mammalian TORC1 Inhibition.
    Tiwarekar V; Wohlfahrt J; Fehrholz M; Scholz CJ; Kneitz S; Schneider-Schaulies J
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29925665
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Replication protein A (RPA) hampers the processive action of APOBEC3G cytosine deaminase on single-stranded DNA.
    Lada AG; Waisertreiger IS; Grabow CE; Prakash A; Borgstahl GE; Rogozin IB; Pavlov YI
    PLoS One; 2011; 6(9):e24848. PubMed ID: 21935481
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strategy of Human Cytomegalovirus To Escape Interferon Beta-Induced APOBEC3G Editing Activity.
    Pautasso S; Galitska G; Dell'Oste V; Biolatti M; Cagliani R; Forni D; De Andrea M; Gariglio M; Sironi M; Landolfo S
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30045985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The C-terminal cytidine deaminase domain of APOBEC3G itself undergoes intersegmental transfer for a target search, as revealed by real-time NMR monitoring.
    Kamba K; Nagata T; Katahira M
    Phys Chem Chem Phys; 2018 Jan; 20(5):2976-2981. PubMed ID: 28905055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural Investigations on the Interactions between Cytidine Deaminase Human APOBEC3G and DNA.
    Yan X; Lan W; Wang C; Cao C
    Chem Asian J; 2019 Jul; 14(13):2235-2241. PubMed ID: 31116511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. APOBEC3DE Antagonizes Hepatitis B Virus Restriction Factors APOBEC3F and APOBEC3G.
    Bouzidi MS; Caval V; Suspène R; Hallez C; Pineau P; Wain-Hobson S; Vartanian JP
    J Mol Biol; 2016 Aug; 428(17):3514-28. PubMed ID: 27289067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of the HIV-1 Vif and Human APOBEC3G Protein Interface.
    Letko M; Booiman T; Kootstra N; Simon V; Ooms M
    Cell Rep; 2015 Dec; 13(9):1789-99. PubMed ID: 26628364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation.
    Bennett RP; Stewart RA; Hogan PA; Ptak RG; Mankowski MK; Hartman TL; Buckheit RW; Snyder BA; Salter JD; Morales GA; Smith HC
    Antiviral Res; 2016 Dec; 136():51-59. PubMed ID: 27825797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apobec3G-Based Strategies to Defeat HIV Infection.
    Ran X; Ao Z; Yao X
    Curr HIV Res; 2016; 14(3):217-24. PubMed ID: 26957196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Translational regulation of APOBEC3G mRNA by Vif requires its 5'UTR and contributes to restoring HIV-1 infectivity.
    Guerrero S; Libre C; Batisse J; Mercenne G; Richer D; Laumond G; Decoville T; Moog C; Marquet R; Paillart JC
    Sci Rep; 2016 Dec; 6():39507. PubMed ID: 27996044
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H.
    Soros VB; Yonemoto W; Greene WC
    PLoS Pathog; 2007 Feb; 3(2):e15. PubMed ID: 17291161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term passage of Vif-null HIV-1 in CD4
    Miyagi E; Kao S; Fumitaka M; Buckler-White A; Plishka R; Strebel K
    Virology; 2017 Apr; 504():1-11. PubMed ID: 28131088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased expression with differential subcellular location of cytidine deaminase APOBEC3G in human CD4(+) T-cell activation and dendritic cell maturation.
    Oliva H; Pacheco R; Martinez-Navio JM; Rodríguez-García M; Naranjo-Gómez M; Climent N; Prado C; Gil C; Plana M; García F; Miró JM; Franco R; Borras FE; Navaratnam N; Gatell JM; Gallart T
    Immunol Cell Biol; 2016 Aug; 94(7):689-700. PubMed ID: 26987686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evasion of adaptive immunity by HIV through the action of host APOBEC3G/F enzymes.
    Grant M; Larijani M
    AIDS Res Ther; 2017 Sep; 14(1):44. PubMed ID: 28893290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanism for APOBEC3G catalytic exclusion of RNA and non-substrate DNA.
    Solomon WC; Myint W; Hou S; Kanai T; Tripathi R; Kurt Yilmaz N; Schiffer CA; Matsuo H
    Nucleic Acids Res; 2019 Aug; 47(14):7676-7689. PubMed ID: 31424549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. APOBEC3G protects the genome of human cultured cells and mice from radiation-induced damage.
    Britan-Rosich Y; Ma J; Kotler E; Hassan F; Botvinnik A; Smith Y; Moshel O; Nasereddin A; Sharma G; Pikarsky E; Ross S; Kotler M
    FEBS J; 2023 Apr; 290(7):1822-1839. PubMed ID: 36325681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.
    Luo K; Wang T; Liu B; Tian C; Xiao Z; Kappes J; Yu XF
    J Virol; 2007 Jul; 81(13):7238-48. PubMed ID: 17428847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A hydrodynamic analysis of APOBEC3G reveals a monomer-dimer-tetramer self-association that has implications for anti-HIV function.
    Salter JD; Krucinska J; Raina J; Smith HC; Wedekind JE
    Biochemistry; 2009 Nov; 48(45):10685-7. PubMed ID: 19839647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distinct Mutagenic Activity of APOBEC3G Cytidine Deaminase Identified in Bladder Cancer.
    Caswell D; Swanton C
    Cancer Res; 2023 Feb; 83(4):487-488. PubMed ID: 36789568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.